Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 11 September 2024, 10:42 HKT/SGT
Share:
    

Source: TR Capital
TR Capital Announces Appointment of Fourth Partner in Drive for Accelerated Growth

- Deepanshu Madan, an Indian national with experience across India and Southeast Asia, becomes the latest partner at Asia’s leading secondary private equity firm

- TR’s India business continues to expand and to capture growing opportunities as one of the first-movers in this space

Singapore and Mumbai, Sept 11, 2024 - (ACN Newswire) - TR Capital, the leading Asian secondary private equity firm, is pleased to announce that Deepanshu Madan has been made the firm’s fourth Partner, marking an important milestone in the firm’s strategic growth.

Deepanshu joined TR Capital seven years ago as a Director, and has since played a pivotal role in the development of the firm’s retail and healthcare portfolio across Asia. In November 2023, he was appointed as the Chief Executive Officer of one of the firm’s portfolio companies, Pharmacity, in Vietnam. At Pharmacity, he is implementing a thorough redesign of the business model to return it to sustainable profitability.

Paul Robine, Founder and CEO of TR Capital, said, “I am thrilled to welcome Deepanshu as our fourth Partner. His exemplary track record over the past seven years, including his exceptional contributions at Pharmacity, underscores the effectiveness of TR’s active investment approach.”

Deepanshu Madan, Partner at TR Capital, said, “I am pleased to be appointed as a Partner at TR Capital and to contribute to the strong investment and ownership culture at the firm. We will continue to push boundaries in developing and supporting our portfolio companies whilst delivering on our active investment approach.”

This new addition to TR Capital’s senior leadership team is a strategic move to bolster the firm’s expansion in key markets, particularly in India. Recent initiatives, including leading the innovative Samara Capital continuation fund and the Fibe secondary direct deal, highlight TR's commitment to advancing its market presence.

In accordance with its growth strategy, TR Capital has recently realigned its local teams at the Director and VP levels to ensure it remains attuned to the dynamics of each local market.

Mr. Robine further commented, “The global secondary market landscape is evolving rapidly, particularly in India, where smaller secondary funds are surfacing alongside established players like TR Capital, creating an increasingly dynamic industry. As a pioneer in this sector, we take great pride in our innovative contributions to the Indian market and look forward to continued success in the future.”

About TR Capital

TR Capital is a leading secondary private equity investor in the Asia-Pacific region, providing liquidity solutions to owners of private equity assets through single asset and portfolio transactions. 

The firm makes significant investments in innovative leaders in the Technology, Next-Generation Consumer and Healthcare sectors across Asia. TR Capital is an active investor and shareholder and works with its portfolio companies to optimize their business models and capital structures. 

TR Capital currently manages funds with aggregate capital commitments of close to US$1.5 billion. The firm’s sophisticated investor base includes sovereign funds, pension funds, asset management firms, entrepreneurs, and family offices.

For more information, please contact:

Artemis Associates

Diana Footitt, CEO

diana.footitt@artemisassociates.com

+852 9183 0667

Dan Bradley, Managing Director

dan.bradley@artemisassociates.com

+852 6145 7455

Bowen Chui, Director

bowen.chui@artemisassociates.com

+852 9783 0643

 




Topic: Press release summary
Source: TR Capital

Sectors: Funds & Equities
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management  
Sept 17, 2024 20:30 HKT/SGT
Discover Exclusive Italian-Made Luxury Products at FIND - Design Fair Asia 2024  
Sept 17, 2024 20:00 HKT/SGT
AI Essentials For Small Businesses to Drive Growth and Save Time  
Sept 17, 2024 17:20 HKT/SGT
JCB and Azer Turk Bank launch JCB merchant acquiring operations across the Republic of Azerbaijan  
Tuesday, September 17, 2024 4:00:00 PM
Fuji frustration for TOYOTA GAZOO Racing  
Tuesday, September 17, 2024 2:01:00 PM
Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner  
Sept 17, 2024 13:30 HKT/SGT
Aryn Hala Announces Launch of Sustainable Cooking Cookbook, Available October 1st  
Sept 17, 2024 11:20 HKT/SGT
Japan International Aerospace Exhibition 2024: Japan's largest comprehensive aerospace industry exhibition  
Tuesday, September 17, 2024 11:00:00 AM
Midea Group Heads For Global Expansion with its ToB Business  
Sept 17, 2024 10:03 HKT/SGT
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)  
Tuesday, September 17, 2024 9:08:00 AM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: